Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alpha-2b in low-risk polycythemia vera
NCT03003325Phase 2Completed
- Sponsor
- Fondazione per la Ricerca Ospedale di Bergamo
- Start
- Feb 2017
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ropeginterferon alfa-2b in polycythemia vera (PV) (2 arms), sponsored by Fondazione per la Ricerca Ospedale di Bergamo. Primary endpoint: Proportion of patients who maintain median HCT < 45% at 12 months. Started Feb 2017; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT03003325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003325.